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Kramecyne is a new peroxide, it was isolated fromKrameria cytisoides, methanol extract, and this plant was mostly found in North
andSouthAmerica.Thiscompoundshowedpotentanti-inflammatoryactivity;however,themechanismsbywhichthiscompound
exerts its anti-inflammatory effect are not well understood. In this study, we examined the effects of kramecyne on inflammatory
responses in mouse lipopolysaccharide- (LPS-) induced peritoneal macrophages. Our findings indicate that kramecyne inhibits
LPS-induced production of tumor necrosis factor (TNF-𝗼) and interleukin- (IL-) 6. During the inflammatory process, levels of
cyclooxygenase- (COX-) 2, nitric oxide synthase (iNOS), and nitric oxide (NO) increased in mouse peritoneal macrophages;
however, kramecyne suppressed them significantly. These results provide novel insights into the anti-inflammatory actions and
support its potential use in the treatment of inflammatory diseases.
1. Introduction
Inflammation is the physiological response of the body to
stimuli, including infections and tissue injury [1]. However,
excessive or prolonged inflammation can prove harmful,
contributing to the pathogenesis of various diseases, includ-
ing arthritis, asthma, multiple sclerosis, inflammatory bowel
disease, and atherosclerosis [2, 3]. Macrophages play critical
roles in the inflammation process.
The LPS-induced inflammation was first understood at
t h es e c o n dh a l fo ft h e1 9 8 0 sb yS t u e h ra n dM a r l e t t a[ 4]. The
macrophages are activated by an LPS-induced inflammatory
responsecausedbythereleaseofseveralinflammatorymedi-
ators including nitric oxide (NO), cyclooxygenase- (COX-)
2, interleukin- (IL-) 6, and tumor necrosis factor- (TNF-) 𝗼
[5, 6].
Therefore, the effect of compounds that prevent inflam-
mation can be evaluated by monitoring the production of
TNF-𝗼, IL-6, and/or NO. The regulation of these mediators
is important for understanding the inflammatory process
and because they serve as a potential site for intervention in
inflammatorydiseases[7].Currentlyinflammatorydisorders
are treated with corticosteroids, nonsteroidal (NSAIDs),
and biologics drugs. However, all of these drugs trigger
a d v e r s es i d ee ff e c t s[ 8]. For these reasons, researchers on
new compounds with anti-inflammatory activity and natural
products are an important source with fewer adverse effects.
Recently the novel compound kramecyne was isolated from
Krameria cytisoides and showed anti-inflammatory activities
in ear edema induced by 12-O-tetradecanoylphorbol-13-
acetate (TPA) and paw edema induced by carrageenan [9].
Hence, the aim of this study wasusing macrophages
a c t i v a t e dw i t hL P St ok n o wt h ee ff e c to fk r a m e c y n eo nt h e
expressions of TNF-𝗼,N O ,i N O S ,C O X - 2 ,a n dI L - 6g e n e si n
ordertoidentifythemechanismofactionofthisnaturalanti-
inflammatory product.
2. Materials and Methods
2.1. Plant Material. K. cytisoides was collected in Las
ComadresMunicipalityofGuadalcazar,SanLuisPotosiState,
Mexico. The identification of the plant was confirmed by
an expert taxonomist. A voucher specimen (SPLM44560)2 Evidence-Based Complementary and Alternative Medicine
Table 1: List of sequences used for RT-PCR.
Gene Sequence Length (bP)
iNOS
Forward: ACCTTGGAGTTCACCCAGT 170
Reverse: ACCACTCGTACTTGGGATGC
COX-2
Forward: GCGAGCTAAGAGCTTCAGGA 212
Reverse: TCATACATTCCCCACGGTTT
TNF-𝗼
Forward: CTGGGACAGTGACCTGGACT 204
Reverse: GCACCTCAGGGAAGAGTCTG
IL-6
Forward: AGTTGCCTTCTTGGGACTGA 159
Reverse: TCCACGATTTCCCAGAGAAC
18s
Forward: GTAACCCGTTGAACCCCATT 140
Reverse: CCATCCAATCGGTAGTAGCG
was deposited into the Isidro Palacios Herbarium of the
Universidad Aut´ onoma de San Luis Potos´ ı.
2.2. Isolation of Kramecyne. Shade-dried leaves of K. cyti-
soideswerereducedtopowder.Aportion(200g)wasdefatted
with hexane (2L) under reflux for 4h and then extracted
into MeOH (2L) under reflux for 4h. The methanol extract
was concentrated to half the original volume under reduced
pressure, and a dark brown solid was obtained with 3% yield
(m.p. 172
∘C, dec.). The compound purity was determined by
thin-layer chromatography. The compound was identified as
kramecyne with FTIR 𝜈cm
−1 (solid) 3332 (O–H), 2919 and
2486 (C–H), 1608 (skeleton), 1443 (C–C), 1284, 1108 (C–O),
and 800 (O–O)
1H-NMR (500MHz, methanol-d4): 𝗿 3.61,
d(11.47),3.63,d(11.47),3.628,d(11.50),3.668,d(11.50),3.69,m,
3.74, dd (3.19).
13C-NMR (500MHz, methanol-d4): 𝗿𝗿 62.12
(CH2), 62.85 (CH2), 63.40 (CH2), 75.15 (C), 73.17 (CH) [9].
2.3. Cell Culture. One and a half milliliters of thioglycolate
medium (4%) was injected into the peritoneal cavity of
BALB/cmice.After72h,macrophageswerecollectedbyperi-
toneal lavage with 10mL cold PBS buffer. The buffer was cen-
trifugedtoisolatethecells.CellswerecountedinaNeubawer
chamber, plated in 12-well plates, and cultured for 24h.
The nonadherent cells were removed, and adherents cells
were cultured with fresh medium. Peritoneal macrophages
wereculturedwithRPMIsupplementedwith10%inactivated
fetal bovine serum (FBS), penicillin (100units/mL), and
streptomycin (100𝜇g/mL) under CO2 (5%) at 37
∘C.
2.4. Cell Viability Using Violet Crystal Exclusion Assay. Peri-
toneal macrophages (1 × 10
6 cells/well) were cultured in
a 12-well plate for 24h in under CO2 (5%) at 37
∘C. The
medium was removed and replaced with fresh medium
containing kramecyne alone and kramecyne plus LPS at
varying concentrations (31.25, 62.5, 125, and 250𝜇g/mL) and
then incubated for 24h. Cell viability was assessed by adding
200𝜇L of 0.4% crystal violet solution followed by incubation
for 30min. At room temperature. After the crystal violet
solution was replaced by acetic acid (33%), it was recovered
and its absorbance was measured at 540nm in a microplate
reader [10].
2 . 5 .D e t e r m i n a t i o no fN i t r i cO x i d eP r o d u c t i o n .Nitrite pro-
duction was measured by the Griess reaction [11]. Peri-
toneal macrophages (1 × 10
6 cells/well) were incubated
overnight. After the medium was removed and replaced
with fresh medium containing kramecyne alone and krame-
cyne plus LPS varying concentrations (31.25, 62.5, 125, and
250𝜇g/mL), macrophages were incubated for 2h. Thereafter,
lipopolysaccharide (LPS, Escherichia coli O111:B4, 1𝜇g/mL)
was added followed by 24h incubation. The supernatant
was collected. One hundred microliters of supernatant
was treated with 100𝜇L of Griess reagent (1% sulphanil-
amide, 0.1% naphtylethylenediamine dihydrochloride, and
5% orthophosphoric acid), and the mixture was incubated
at room temperature for 5min. Then the absorbance was
measured at 540nm in a microplate reader. The amount of
nitriteinthesamplewas determinedusingsodiumnitritefor
the standard curve.
2.6.RT-PCRAnalysisofmRNA. Peritoneal macrophages (2 ×
10
6 cells/well)wereculturedkramecynealoneandkramecyne
and LPS, varying concentrations of kramecyne (31.25, 62.5,
125, and 250𝜇g/mL) in 12-well plates for 2h, stimulated
with LPS (1𝜇g/mL), and incubated for 24h. The inhibitory
effect of kramecyne on mRNA expression of proinflam-
matory cytokines (IL-6 and TNF-𝗼) and mediators (iNOS
and COX-2) was determined by semiquantitative RT-PCR.
The PCR products were normalized to the amount of 18S
ribosomalRNA.PrimersweredesignedusingPrimerBLAST
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/)( Table 1).
2.7. Measurement of the Production of Proinflammatory
Cytokines (TNF-𝗼 and IL-6). Peritoneal macrophages were
cultured with varying concentration of kramecyne (31.25,
62.5, 125, and 250𝜇g/mL) in 12-well culture plates for 2h,
stimulated with LPS (1𝜇g/mL), and incubated for 24h. The
inhibitory effect of kramecyne on the production of proin-
flammatory cytokines (IL-6 and TNF-𝗼) was determined by
examining the collected supernatants. Cytokines concentra-
tion was measured using a mouse ELISA kit (eBioscience).
2.8. Statistical Analysis. All values were expressed as the
mean ± SEM. The differences between mean values of nor-
mallydistributeddatawereassessedwithaone-wayANOVA
(Newman Keuls t-test). Statistical significance was accepted
at 𝑃 < 0.05.
3. Results
3.1. Effect of Kramecyne on Cell Viability. The effect of
k r a m e c y n ea n dk r a m e c y n ep l u sL P So nt h ec e l lv i a b i l i t yo f
peritoneal macrophages is shown in Figure 1.Th e s ec o m -
pounds did not demonstrate any toxicity at the conditions
tested (31.25, 62.5, 125, and 250𝜇g/mL).
3 . 2 .I n h i b i t o r yE ff e c to fK r a m e c y n ei nt h eN OP r o d u c t i o ni n
Peritoneal Macrophages. We found that macrophages pro-
duced considerable amount of NO under basal conditions.
After stimulation with LPS, NO production was increasedEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Effect of kramecyne on cell viability in peritoneal
macrophages.Peritonealmacrophagesweretreatedwithkramecyne
at 31.25, 62.5, 125, and 250𝜇g/mL in the presence or absence of
1𝜇g/ml LPS for 24hrs. Cell viability was examined with violet
crystal. Results are expressed as the percentage of surviving cells
relative to control cells. Date represent mean ± SEM of three
independent experiments; each was performed in triplicate.
significantly. However, when kramecyne was added at 31.25,
62.5, 125, and 250𝜇g/mL, the NO levels were diminished by
5.3, 11.0, 37.0, and 47.3%, respectively (Figure 2). No signifi-
cant difference in NO levels was found between cells under
basal conditions and those treated with 125 or 250𝜇g/mL of
compound.
3.3. Inhibitory Effect of Kramecyne on iNOS, COX-2, TNF-
𝗼, and IL-6 mRNA Expression in LPS-Stimulated Peritoneal
Macrophages. The expression of iNOS and COX-2 mRNAs
was increased in LPS-stimulated macrophages. Kramecyne
inhibited iNOS production in a concentration-dependent
manner.At31.25,62.5,125,and250𝜇g/mL,kramecyneinhib-
ited iNOS significantly (53.4, 68.0, 80.0, and 88.7%, resp.)
(Figure 3(a)).Atconcentrationof125and250𝜇g/mL,krame-
cyne completely suppressed mRNA expression of COX-2
mRNA (Figure 3(b)).
Kramecyne also significantly inhibited the expression
of TNF-𝗼 a n dI L - 6i nL P S - s t i m u l a t e dm a c r o p h a g e s ,a n d
the effect was concentration dependent (Figure 3(c)). TNF-𝗼
expression diminished by 65.0, 68.7, 71.5, and 90.0% at 31.25,
6 2 . 5 ,1 2 5 ,a n d2 5 0 𝜇g/mL, respectively. In the case of IL-6,
kramecyne suppressed its expression by 60.0, 70.8, 78.0, and
90.7% (Figure 3(d)).
3.4. Inhibitory Effect of Kramecyne on TNF-𝗼 a n dI L - 6P r o -
duction in LPS-Stimulated Peritoneal Macrophages. Krame-
cyne significantly reduced TNF-𝗼 and IL-6 production in
LPS-activated macrophages, and the responses were dose
dependent (Figures 4(a) and 4(b)). TNF-𝗼 was significantly
inhibited by kramecyne at 31.25, 62.5, 125, and 250𝜇g/mL
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Figure 2: Effect of kramecyne on NO production in peritoneal
macrophages LPS stimulated. The Griess reagent assay was carried
out to measure nitrite produced as described in the materials
and methods. Date represent mean ± SEM of three independent
experiments performed in triplicate;
∗∗P < 0.05 versus basal and
kramecyne group;
∗P < 0.05 versus LPS group.
(37.3, 40.4, 48.0, and 81.0%, resp.). At 250𝜇g/mL, krame-
cyne completely suppressed IL-6 production as compared to
macrophages under basal condition.
4. Discussion
Inflammation is the first response of the immune system to
infection or irritation, and macrophages play a crucial role
during the inflammatory process [12]. Lipopolysaccharide
(LPS) is an endotoxin, an integral outer membrane com-
ponent of Gram-negative bacteria, and triggers the most
potentmicrobialinitiatorsofinflammatoryresponse,includ-
ing septic shock, fever, and microbial invasion [13]. Murine
and human macrophages exhibit a particularly vigorous
response to LPS, which induces a variety of inflammatory
modulators such as NO, TNF-𝗼,I L - 6 ,a n dP G s[ 14]. These
proinflammatory mediators are regarded as essential anti-
inflammatorytargets[15, 16]. For this reason, the stimulation
macrophages with LPS constitute an excellent model for
t h es c r e e n i n ga n ds u b s e q u e n te v a l u a t i o no ft h ee ff e c t so f
candidate drugs on the inflammatory pathway. The excessive
or prolonged inflammation can prove harmful, contributing
to the pathogenesis of a variety of diseases, including arthri-
tis, asthma, multiple sclerosis, inflammatory bowel disease,
and atherosclerosis [17–19]. Therefore, agents that regulate
cytokines and inflammatory mediators may have therapeutic
effects. Various in vivo and in vitro experimental models
have been set up to assess inhibitory effect of various natural
products on these inflammatory mediators [20–25].
NOisanintracellularmessengerwhichregulatesvascular
relaxation and participates in the process of elimination of4 Evidence-Based Complementary and Alternative Medicine
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Figure3:EffectofkramecyneonLPS-inducedmRNAexpressionof(a)iNOS,(b)COX-2,(c)TNF-𝗼,and(d)IL-6inperitonealmacrophages.
Total RNA (1 𝜇g) was prepared and analyzed by RT-PCR, as described in the material and methods. Date represent mean ± SEM of three
independent experiments;
∗∗P < 0.05 versus basal and kramecyne group;
∗P < 0.05 versus LPS group.
pathogens and tumour cells, and it is involved in promoting
inflammatory responses [26–28]. Evidence indicates that
excessive production of NO resulted in excess inflammatory
r e a c t i o nd e l e t e r i o u st ot h eh u m a nb o d yi nt h ei n fl a m m a -
tion process [26, 29–31]. NO by macrophages may lead to
v a r i o u sp a t h o l o g i c a ld i s o r d e r ss u c ha si n fl a m m a t i o na c u t e
and chronic [32], carcinogenicity, cytotoxicity, and autoim-
mune diseases [33]. The free radical nature on NO and its
high reactivity allow NO to react with oxygen to produce
peroxynitrite (ONOO
−), which make it a potent pro-oxidant
molecule that is able to induce oxidative damage, and can be
potentially harmful towards cellular targets [34]. Therefore,
NO production can be used as a measure of the progres-
sion of inflammation and inhibition of NO might have
potential therapeutic value when related to inflammation-
associated disease [35]. NO is produced in physiological
and pathophysiological conditions by three distinct isoforms
of nitric oxide synthase (NOS): endothelial NOS (eNOS),
neuronal NOS (nNOS), and inducible NOS (iNOS) [36, 37],
while eNOS and nNOS are constitutively expressed and
regulated by Ca
2+-calmodulin [38]. The activity of iNOS
is regulated at the transcription levels by mediators suchEvidence-Based Complementary and Alternative Medicine 5
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Figure 4: Inhibitory effect of kramecyne on the (a) TNF-𝗼 and (b) IL-6 cytokines production in peritoneal macrophages. Concentration in
the supernatants was determined by ELISA. The results are the mean values ± SEM for five independent experiments;
∗∗P < 0.05 versus basal
and kramecyne group;
∗P < 0.05 versus LPS group.
as IL-1, IL-6, INF-𝗾,a n dT N F - 𝗼 [39, 40]. Although TNF-
𝗼 is not an inducer of iNOS, it is crucial for synergistic
induction of NO synthesis in INF-𝗾 and/or LPS-stimulated
murine peritoneal macrophages and regulates NO synthesis
in vivo [41]. Therefore, a direct and/or indirect modulation
of macrophage-mediated NO production may reduce these
inflammatory diseases. In the present study, we examined
the mechanism of action of kramecyne and found that this
compound decreased NO production and iNOS expression
inLPS-stimulatedmacrophagesperitonealmacrophages,and
this effect was independent of concentration (Figure 2).
Cyclooxygenase-2 (COX-2) is expressed in response to
inflammatory and other physiological stimuli and growth
factors. It is involved in the synthesis of prostaglandins
(PG) that mediated temperature and pain and supported
the inflammation process [42, 43]. COX-2 is found in high
concentrations in patients with inflammatory diseases, and
the levels of PGs are increased if inflammation continues
[44, 45]. The inhibition of COX-2 is clinically relevant
because PG production is thought to be responsible for
the antipyretic, anti-inflammatory, and analgesic proprieties
of NSAIDs [46]. NSAIDs inhibit both isoforms of COX,
and their adverse effects, mainly gastrointestinal ulcers, are
attributed to the inhibition of the release of gastroprotective
prostaglandins produced via COX-1 pathways [47,48].Many
studies have demonstrated that compounds that selectively
inhibit COX-2 cause less damage to gastric mucosa [8].
Our results showed that kramecyne significantly attenuated
COX-2 mRNA expression at 250𝜇g/mL in LPS-stimulated
macrophages.Therefore,itseemsquitereasonabletopropose
that kramecyne inhibits PGE2s production. Moreover, fur-
ther studies are required to determine whether kramecyne is
a selective inhibitor of COX-2.
Inflammatory disorders are characterized by the produc-
tion of a significant amount of cytokines such as TNF-𝗼,
IL-6, and IL-1𝗽 [49]. TNF-𝗼 is a potent proinflammatory
cytokine,commonlyreleasedbymacrophages.I tupregula ted
other proinflammatorycytokines like IL-6 that is responsible
for the induction and perpetuation of inflammation [50].
Thesecytokinesmaycauseseveretissuedamage,septicshock,
atherosclerosis, cytotoxicity, and rheumatoid arthritis [51,
52].Thesetwocytokinesareknowntoactasproinflammatory
mediators in vitro and in vivo.
IL-6 is a multifunctional cytokine with pro- and anti-
inflammatory properties that plays a central role in the
regulation of defense mechanisms, haematopoiesis, and the
production of acute phase proteins [53]. In addition, the
overexpressionofIL-6isinvolvedinphysiologicalconditions
such as rheumatoid arthritis [54]. In this study, we found
that kramecyne reduced TNF-𝗼 and IL-6 mRNA expres-
sions and secretion, in LPS-stimulated macrophages, in a
concentration-dependent manner (Figure 3).
Previousstudieshavedemonstratedthattheexpressionof
iNOS is stimulated by proinflammatory cytokines, including
IL-1𝗽 and TNF-𝗼, which contribute to tissue damage and
multiple organ failure [55]. Additionally, Schrader et al. [56]
suggested that TNF-𝗼 stimulates IL-6 production and that
this is a prerequisite for increased NO production. These
results suggest that the inhibitionof iNOS/NO by kramecyne
may be associated with the attenuation of TNF-𝗼 and IL-6
production.
Many studies have demonstrated that the expression of
enzymes and cytokines proinflammatory are largely regu-
lated by transcription activation. Nuclear factor kappa B
(NF𝜅B) is essential for the transcription of genes that encode
for inflammatory molecules which participate in the acute6 Evidence-Based Complementary and Alternative Medicine
inflammatory responses, including iNOS, COX-2, TNF-𝗼,
and IL-6 in the monocyte-macrophage lineage, and this
transcription factor is activated by LPS [57]. However, this
study is limited to understand the effect of kramecyne on
gene expression of iNOS, COX-2, TNF-𝗼,a n dI L - 6a n dt h e
production of NO. Therefore, it will be interesting to under-
stand the effect of kramecyne at transcriptional activation
level involving NF𝜅B protein. This transcription factor plays
a crucial role in the regulation of cellular responses, and the
mitigation of this factor is considered a good therapeutic
option for inflammation. Our results demonstrated that
kramecyne inhibited the mediators regulated for NF𝜅B, and
this fact might suggest that this compound acts on the
transcriptionfactor,butotherstudiesarerequiredtoconfirm
this proposal.
Kramecyne showed anti-inflammatory activities in TPA-
induced mouse ear edema and carrageenan-induced rat paw
edema. It has been observed that kramecyne does not exhibit
toxic effects even at a dose of 5000mg/kg in a model of
acute toxicity [9]. Taken together with the cells viability
studies, these results support the low toxicity of kramecyne
andencouragethepossibilityofusingitasanti-inflammatory.
5. Conclusion
Kramecyne is a potent inhibitor of iNOS, COX-2, NO, TNF-
𝗼, and IL-6 production at the transcriptional level in LPS-
stimulated macrophages. The mechanism of inhibition for
NO production appears to be due to a downregulation of
iNOS mRNA expression, which might be associated with
the attenuation of TNF-𝗼 and IL-6 production. Although
the exact mechanisms for the anti-inflammatory activity of
kramecyne are not fully known, these findings suggest that
kramecyne may be as potent compound for the treatment of
inflammatory diseases.
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